Key Takeaways
- Infilbray (venglustat) is the first approved treatment for the neurological manifestations of Type 3 Gaucher disease
- In the 43-patient LEAP2MONO trial it beat imiglucerase on a combined ataxia-and-cognition endpoint (p=0.0137)
- The once-daily pill crosses the blood-brain barrier, which enzyme replacement therapy cannot do
The symptoms no Gaucher drug could treat — until now
Type 3 Gaucher disease damages more than the body. Alongside the enlarged organs and bone problems of the rare inherited disorder, it attacks the brain and nervous system — causing ataxia, cognitive decline and seizures.
For decades, enzyme replacement therapies treated the body. They could not cross the blood-brain barrier, so the neurological symptoms went untreated.
On November 18, the U.S. Food and Drug Administration approved Infilbray (venglustat) — the first treatment for the neurological manifestations of Type 3 Gaucher disease, for adults and for children weighing at least 15 kg.
Infilbray is a once-daily oral tablet made by Genzyme, a Sanofi company. It works differently from enzyme therapy: it reduces production of the fatty substances that build up in Gaucher disease, and it can cross into the brain.
A small trial, a clear result
The approval rests on the Phase 3 LEAP2MONO trial, which enrolled 43 patients aged 12 and older who had been on enzyme therapy for at least three years.
Patients received either Infilbray with a placebo infusion, or intravenous imiglucerase — the standard enzyme therapy — with a placebo tablet, for 52 weeks.
On the combined primary endpoint, measuring change in ataxia (mSARA) and cognition (RBANS) scores, Infilbray showed statistically significant superiority over imiglucerase (p=0.0137).
The drug carries real cautions. Its warnings include suicidal ideation and behaviour, clouding of the lens in children's eyes, and harm to a developing fetus. The most common side effects seen more often than with imiglucerase included diarrhea and nausea.
The FDA granted the drug Orphan Drug designation and a Priority Review.
Health note: Type 3 Gaucher disease is a very rare inherited disorder, and this approval is based on a single trial of 43 patients already stable on enzyme therapy. Infilbray is approved in the United States; it is not a Health Canada approval, and treatment decisions belong with the specialists who manage this disease.
The Twikup Take
For families living with Type 3 Gaucher, the brain symptoms were the part medicine openly could not touch. A pill that crosses the blood-brain barrier and beat standard therapy on a combined movement-and-cognition endpoint is a genuine first — with the small print that 43 patients is a small evidence base, and the safety warnings are serious.
Image: Illustrative image.
